Ruchika Sangani

Ruchika Sangani

Auto-generated profile, based on publicly available information

Ruchika Sangani

Pulmonary Center, Boston University Chobanian & Avedisian School of Medicine, Boston, MA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2024 in Chest
Verified
Journal Article
Closed access
RSRuchika Sangani
Ruchika Sangani
NBNicholas A. Bosch
Nicholas A. Bosch
PGPraveen Govender
Praveen Govender
BSBrittany Scarpato
Brittany Scarpato
AWAllan J. Walkey
Allan J. Walkey
DSDivya A. Shankar
Divya A. Shankar

1 October 2022 in Pulmonary Circulation
Verified
Journal Article
Open access
RSRuchika A. Sangani
Ruchika A. Sangani
JLJustin K. Lui
Justin K. Lui
KGKari R. Gillmeyer
Kari R. Gillmeyer
MTMarcin A. Trojanowski
Marcin A. Trojanowski
ABAndreea M. Bujor
Andreea M. Bujor
EKElizabeth S. Klings
Elizabeth S. Klings
Patients with systemic sclerosis complicated by both pulmonary hypertension (SSc‐PH) and interstitial lung disease (SSc‐PH‐ILD) have poor prognosis compared to those with SSc‐PH or SSc‐ILD alone. Little is known of how ILD severity affects outcomes in those with SSc‐PH, or how PH severity affects outcomes in those with SSc‐ILD. Herein, we aimed to delineate clinical features of patients with SSc‐PH and SSc‐ILD and determine to what degree PH and ILD severity contribute to mortality in patients with SSc. We conducted parallel retrospective studies in cohorts of patients with SSc‐PH and SSc‐ILD. We categorized ILD severity by pulmonary function testing and PH severity by cardiopulmonary hemodynamics. Our primary outcome was all‐cause mortality from time of PH or ILD diagnosis for the SSc‐PH and SSc‐ILD cohorts, respectively. We calculated adjusted risks of time to all‐cause mortality using Cox proportional hazards models. In patients with SSc‐PH, severe ILD (HR: 3.54; 95% CI: 1.05, 11.99) was associated with increased hazards for all‐cause mortality. By contrast, mild and moderate ILD were not associated with increased mortality risk. In patients with SSc‐ILD, both moderate (HR: 2.65; 95% CI: 1.12, 6.31) and severe PH (HR: 6.60; 95% CI: 2.98, 14.61) were associated with increased hazards for all‐cause mortality, while mild PH was not. Through our parallel study design, the risk of all‐cause mortality increases as severity of concomitant ILD or PH worsens. Therapies that target slowing disease progression earlier in the disease course may be beneficial.

15 April 2024 in CHEST Pulmonary
Verified
Journal Article
Open access
RSRuchika Sangani
Ruchika Sangani
MLMing-Ming Lee
Ming-Ming Lee
HXHanfei Xu
Hanfei Xu
JDJosée Dupuis
Josée Dupuis
GOGeorge T. O’cOnnor
George T. O’cOnnor
Lung function declines over the course of adulthood; however, a consensus on the normal range of decline in an individual’s lung function is lacking. What is the normal range and the upper limit of normal (ULN) decline in lung function in adults without prior tobacco use, occupational dust exposure, or a known diagnosis or symptoms of cardiopulmonary disease? A retrospective analysis of healthy individuals who have never smoked (N = 1,305) from the Framingham Heart Study with repeated lung function meeting standards for acceptability and reproducibility was conducted. Longitudinal change was derived using a linear mixed effects model and estimated to a 6-year interval. The ULN decline was defined as the 95th percentile. The mean follow-up between spirometry examinations was 5.5 years, whereas the mean follow-up between diffusing capacity for carbon monoxide studies was 5.9 years. Decline in FEV1, FVC, and D accelerated with age, whereas decline in FEV1/FVC decelerated with age. Decline varied with sex, age, and height. Over a 6-year period, the ULN decline in FEV1 ranged from 383 to 667 mL, and the ULN decline in Dlco ranged from 3.6 to 9.5 mL/min/mm Hg. Overall, male individuals had faster absolute rates of decline than female individuals, whereas relative (%) rates of decline were similar between sexes. Lung function decline is nonlinear and accelerates with age. In this cohort, the ULN decline over 6 years often exceeded current guidelines for interpreting significant longitudinal change in lung function.

13 November 2023 in Lung
Verified
Journal Article
Closed access
PDF file
JLJustin K. Lui
Justin K. Lui
KGKari R. Gillmeyer
Kari R. Gillmeyer
RSRuchika A. Sangani
Ruchika A. Sangani
RSRobert Smyth
Robert Smyth
DGDeepa M. Gopal
Deepa M. Gopal
EKElizabeth S. Klings
Elizabeth S. Klings

1 June 2023 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
BPBrandon Pang
Brandon Pang
LKLauren Kearney
Lauren Kearney
JMJennifer Maccarone
Jennifer Maccarone
JZJingzhou Zhang
Jingzhou Zhang
CKChristopher Kearney
Christopher Kearney
NBNicholas A. Bosch
Nicholas A. Bosch

15 April 2023 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
NMNathan Mesfin
Nathan Mesfin
RSRuchika Sangani
Ruchika Sangani
DSDivya A. Shankar
Divya A. Shankar
CRChristine Reardon
Christine Reardon